A theme involving the acquisition from Taiwan-based Steminent of exclusive development and commercialization rights in Japan for Stemchymal® (for spinocerebellar degeneration), followed by development toward an application for marketing approval in Japan. This is the company's initial product introduction project as it makes a full-scale entry into the regenerative medicine field.